Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III StudyRobert J. Motzer, Theodore Stewart Gourdin, Camillo Porta et al.|Journal of Clinical Oncology|2024Cited by 170
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trialBrian I. Rini, Thomas Powles, Tom Waddell et al.|Nature Medicine|2025Cited by 44